India's Richest People 2026 edition · 1 director · Source: Hurun India
- #1,028 M Sivakumaran ₹2,600 Cr
Revenue · FY 2025
₹23.52 Cr
▼ 14% YoY
Net loss · FY 2025
₹62.75 Cr
Net margin -266.9%
EBITDA · FY 2025
-₹35.91 Cr
EBITDA margin -152.7%
Authorised capital
₹450.1 Cr
Registered with MCA
Paid-up capital
₹336.1 Cr
Issued & subscribed
Company age
14 yrs
Est. 2012
Employees · EPFO
169
Provident fund records
Directors on board
7
As per MCA filings
About Auro Peptides Limited
Data last updated:
Auro Peptides Limited is a public limited company based in Hyderabad, Telangana, India, a subsidiary of Aurobindo Pharma Ltd. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 02 January 2012 and has been in existence for over 14 years.
Its director M Sivakumaran is #1,028 among India's richest people (2026).
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN U24232TG2012PLC078350. Its GSTIN is 36AAKCA1234F1Z1 (Telangana). The company holds 3 GST registrations, of which 1 is active.
The company has an authorised share capital of ₹450.1 Cr and a paid-up capital of ₹336.1 Cr. It is led by directors including Chandra Reddy Tirumalareddy (Whole-Time Director) and Sivakumaran Meenakshisunderam.
Its last annual general meeting (AGM) was held on 01 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Galaxy Floors 22 – 24 Plot No. 1 Survey No. 83/1 Hyderabad Knowledge City Raidurg Panmak, Tha, Telangana, India – 500032.
As per the financials filed for FY 2025, the company reported a revenue of ₹23.52 Cr, a decline of 14% compared to the previous year. For the same year it recorded a net loss of ₹62.75 Cr (net margin -266.9%) and EBITDA of -₹35.91 Cr (EBITDA margin -152.7%). Revenue has grown at a compounded annual rate (CAGR) of 16% over three years and 12% over five years.
The company has about 169 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Aurobindo Pharma. Court records list 4 cases involving the company, including 4 filed by the company; 4 cases are pending. The company has 6 deals on record (6 funding rounds), with disclosed funding of ₹201.8 Cr; the latest was in March 2022. Its 3 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 1 larger and 2 smaller; the largest is Chemgenix Laboratories Private Limited with revenue of ₹23.72 Cr. The company has 10 MSME Form 1 returns on record between 2017 and 2023, listing 74 overdue payments to 25 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website aurobindo.com.
Company details
CIN U24232TG2012PLC078350
Registration Number 078350
Incorporation Date 02 January 2012
ROC Hyderabad
Listing Status Unlisted
Company Status Active
Date of Last AGM 01 September 2025
Date of Balance Sheet 31 March 2025
Parent Company Aurobindo Pharma Ltd
Compliance Status Active Compliant
CIN history
Auro Peptides has one previous CIN (Corporate Identification Number): U24232AP2012PLC078350. The current CIN is U24232TG2012PLC078350, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24232TG2012PLC078350 | Current |
| U24232AP2012PLC078350 | Previous |
Key People
Chandra Reddy Tirumalareddy Whole-Time Director Sivakumaran Meenakshisunderam Director Mudiraj Saritha Rani Director Recognitions & Rankings of Auro Peptides
Contact details
Auro Peptides Limited's registered office is in Hyderabad, Telangana. Its website is aurobindo.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressGalaxy Floors 22 – 24 Plot No. 1 Survey No. 83/1 Hyderabad Knowledge City Raidurg Panmak, Tha, Telangana, India – 500032
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Auro Peptides Limited, buy the company report.
Comprehensive company report
Auro Peptides Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Auro Peptides operates one associated brand: Aurobindo Pharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Generic biocatalytic solutions are provided for pharmaceutical applications. | aurobindo.com |
Business activity
The main business activity of Auro Peptides is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Auro Peptides Limited, buy the company report.
Financials of Auro Peptides Limited
FY 2025 filings availableAuro Peptides Limited reported revenue of ₹23.52 Cr (down 14% YoY) for FY 2025.
Revenue · FY 2025
₹23.52 Cr ▼ 14%
Net loss · FY 2025
₹62.75 Cr margin -266.9%
EBITDA · FY 2025
-₹35.91 Cr margin -152.7%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▼ 14%
3 years · compounded
▲ 16%
5 years · compounded
▲ 12%
EBITDA CAGR growth
1 year
▼ 26%
3 years · compounded
▼ 31%
5 years · compounded
▼ 27%
Revenue fell 14% in the latest year, but over five years it has grown at a compounded annual rate (CAGR) of 12%. EBITDA fell 26% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | -₹35.91 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | -₹62.75 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | -152.7% | ||||
| Net Profit Margin | -266.9% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Auro Peptides Limited, buy the company report.
Board of directors of Auro Peptides Limited
Auro Peptides has 7 current directors and 16 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Sivakumaran Meenakshisunderam Also directs: Curateq Biologics Private Limited, Tergene Biotech Limited, Apl Healthcare Limited and 2 more | Director | 29 Sep 2017 | 9 Years 0 Months | Current |
| Mudiraj Saritha Rani | Director | 15 Jun 2022 | 4 Years 4 Months | Current |
| Chandra Reddy Tirumalareddy | Whole-Time Director | 23 May 2019 | 7 Years 5 Months | Current |
| Mylandlahalli Rammohan Ashwini Also directs: Curateq Biologics Private Limited, Apl Healthcare Limited, Auro Vaccines Private Limited and 3 more | Additional Director | 30 Oct 2025 | 0 Years 11 Months | Current |
| Satakarni Makkapati Also directs: Aurobindo Pharma Ltd, Engenra Biologics Private Limited, Theranym Biologics Private Limited and 2 more | Director | 02 Nov 2021 | 4 Years 11 Months | Current |
| Naga Venkata Subbarao Kesavarapu | Director | 20 Jan 2023 | 3 Years 9 Months | Current |
Showing 6 of 7 current directors. View all directors
Peer comparison
Auro Peptides Limited is compared with the 3 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Chemgenix Laboratories Private Limited | ₹23.72 Cr (FY 2025) | -1.0% | Hyderabad, Telangana, India | |||
| Auro Peptides Limitedthis company | ₹23.52 Cr (FY 2025) | -₹62.75 Cr | -266.9% | -14.0% | 169 | Hyderabad, Telangana, India |
| Medisol Lifescience Private Limited | ₹23.51 Cr (FY 2024) | 158.0% | Mumbai, Maharashtra, India | |||
| Precept Pharma Limited | ₹23.38 Cr (FY 2025) | -6.0% | Chandigarh, India |
To see the full peer comparison of Auro Peptides Limited, buy the company report.
Auditor
Auro Peptides Limited is audited by Reddy AV &Co for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Reddy AV &Co | FY 2023 | 003256S |
Shareholding
The shareholding of Auro Peptides Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Auro Peptides Limited, buy the company report.
Deals & funding
Auro Peptides Limited has 6 deals on record (6 funding rounds), with disclosed funding of ₹201.8 Cr; the latest was in March 2022.
Total deals
6
Funding rounds
6
Disclosed funding
₹201.8 Cr
Deals on record (1 of 6)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Jul 2012 | Funding round | ₹5 Lakh | Investors: Aurobindo Pharma Ltd , an individual |
To see the full deal history of Auro Peptides Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Auro Peptides Limited has 4 court cases on record: 4 filed by Auro Peptides. All cases are pending.
Total cases
4
Filed by the company
4
Pending
4
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 4 | 0 | 4 |
Cases on record (3 of 4)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court, TELANGANA | Writ petition | Filed by the company against Assistant Commissioner, and 3 others | Pending |
| High Court, TELANGANA | Writ petition | Filed by the company against Assistant Commissioner and 3 others | Pending |
| High Court, TELANGANA | Writ petition | Filed by the company against Assistant Commissioner and 3 Others and 3 others | Pending |
To see the full case history of Auro Peptides Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Auro Peptides Limited has 10 MSME Form 1 returns on record between 2017 and 2023, listing 74 overdue payments to 25 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 25)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Infinium Pharmachem Limited | |||
| Sujata Nutri-Pharma Private Limited | |||
| an individual supplier | |||
| Smart Labtech Private Limited | |||
| an individual supplier |
To see the full MSME payment records of Auro Peptides Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Auro Peptides Limited has a workforce of 169 employees on its EPFO records as of Apr 06, 2024, across 1 active EPFO establishment.
Employee count
169
Active EPFO establishments
1
Employee growth
25.19%
GST
Auro Peptides has 3 GST registrations: 1 active and 2 cancelled or inactive.
Total GSTINs
3
Active
1
Cancelled / inactive
2
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 36AAKCA1234F1Z1 | Telangana | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Auro Peptides Limited, buy the company report.
Recent activity
Auro Peptides Limited has 20 board changes on record since 2017: 7 appointments and 13 cessations. The latest: Mylandlahalli Rammohan Ashwini was appointed as Additional Director on 30 Oct 2025.
Appointed
Mylandlahalli Rammohan Ashwini was appointed as Additional Director.
Ceased
Mylandlahalli Rammohan Ashwini ceased to be CFO.
Appointed
Rajendra Rekapu Krishna was appointed as Additional Director.
AGM
Auro Peptides Limited last Annual general meeting of members was held on 01 Sep 2025 as per latest MCA records.
Filing
Auro Peptides Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Hyderabad.
Ceased
Naga Venkata Subbarao Kesavarapu ceased to be Additional Director.
Appointed
Naga Venkata Subbarao Kesavarapu was appointed as Director.
Ceased
Singhal Shilpa ceased to be Director.
Ceased
Satakarni Makkapati ceased to be Additional Director.
Ceased
Mudiraj Saritha Rani ceased to be Additional Director.
Appointed
Mudiraj Saritha Rani was appointed as Director.
Ceased
Venkateswararao Kondreddy ceased to be Director.
11 earlier events are in the company report.
News
Frequently asked questions
Auro Peptides is an active public limited company based in Hyderabad, Telangana, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 02 January 2012 (14+ years old) and is registered under CIN U24232TG2012PLC078350.
Auro Peptides has 7 current directors:
- Chandra Reddy Tirumalareddy - Whole-Time Director
- Sivakumaran Meenakshisunderam - Director
- Mudiraj Saritha Rani - Director
- Mylandlahalli Rammohan Ashwini - Additional Director
- Satakarni Makkapati - Director
- Naga Venkata Subbarao Kesavarapu - Director
- Rajendra Rekapu Krishna - Additional Director
The latest financial statements of Auro Peptides on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 01 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Auro Peptides is 36AAKCA1234F1Z1, registered in Telangana. The company has 3 GST registrations in all, of which 1 is active and 2 are cancelled or inactive.
The CIN (Corporate Identification Number) of Auro Peptides is U24232TG2012PLC078350. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Auro Peptides has 4 court cases on record: 4 filed by the company. 4 are pending.
Auro Peptides was incorporated on 02 January 2012, making it 14+ years old. It is registered with the Registrar of Companies, Hyderabad.
Auro Peptides has 6 deals on record (6 funding rounds), with disclosed funding of ₹201.8 Cr; the latest was in March 2022.
The peers of Auro Peptides by revenue are Chemgenix Laboratories Private Limited, Medisol Lifescience Private Limited, Precept Pharma Limited, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Mylandlahalli Rammohan Ashwini was appointed as Additional Director on 30 Oct 2025. Mylandlahalli Rammohan Ashwini ceased to be CFO on 30 Oct 2025. Rajendra Rekapu Krishna was appointed as Additional Director on 30 Oct 2025. Auro Peptides has 20 board changes on record in total.
Auro Peptides has 10 MSME Form 1 returns on record between 2017 and 2023, listing 74 overdue payments to 25 micro and small suppliers. The latest return was filed on 28 Aug 2023.
Auro Peptides can be reached through the website aurobindo.com. Its registered office is in Hyderabad, Telangana, India.